The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 Multi-Center Clinical Trial (safety and effectiveness trial) in 60 patients
(40 denosumab; 20 placebo) who have had a kidney transplant for 12-months or longer with more
than 30% of kidney function. The investigators will test whether denosumab safely improves
bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) and improves bone
strength by high resolution peripheral quantitative computed tomography (HR-pQCT) in the
subset of patients recruited at Columbia University Irving Medical Center. These data will
inform the development and execution of a larger trial to test if denosumab prevents
fractures in kidney transplant recipients.